Tag Archives: eisai

January, 2018

19 January
Adlai Nortye Enters into Global Licensing Agreement with Eisai for EP4 Antagonist

HANGZHOU, China, Jan. 19, 2018 /PRNewswire/ — Adlai Nortye Biopharma Co., Ltd. (NEEQ: 870946) (“Adlai Nortye” or “the Company”), a biopharmaceutical company dedicated to discovery and commercialization of new and effective drugs, announced today that it had entered into a Global Licensing Agreement (“the Agreement”) with Eisai Co., Ltd. (“Eisai”), …
Share
9 January
FDA Grants Breakthrough Therapy Designation to Eisai and Merck’s Kidney Cancer Combo Therapy

TOKYO and KENILWORTH, N.J., Jan. 9, 2018 /PRNewswire/ — Eisai Co., Ltd. and Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that they received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Eisai’s multiple receptor tyrosine kinase inhibitor LENVIMA® (lenvatinib) …
Share

21 December
Eisai and Biogen’s Alzheimer’s Disease Drug Fails in Mid-Stage Trial

CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced today that an Independent Data Monitoring Committee has determined that BAN2401, an anti-amyloid beta protofibril antibody, did not meet the criteria for …
Share

23 October
Biogen and Eisai Expand Collaboration for Development of Aducanumab in Alzheimer’s Disease

CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced today that the companies have expanded their existing agreement to jointly develop and commercialize investigational Alzheimer’s disease treatments. Under the terms of …
Share

27 September
FDA Accepts sNDA for Eisai’s Lenvatinib for the Treatment of Hepatocellular Carcinoma

WOODCLIFF LAKE, N.J., Sept. 26, 2017 /PRNewswire/ — Eisai Inc. today announced the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for lenvatinib (marketed as Lenvima®) for the potential use in the first-line treatment of patients with hepatocellular carcinoma (HCC), commonly referred to as liver cancer. …
Share

1 June
Eisai and John Hopkins Extend Drug Discovery Collaboration with New Licensing Agreement

WOODCLIFF LAKE, N.J., May 31, 2017 /PRNewswire/ — Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., and Johns Hopkins University announced today that they have extended their drug discovery collaboration through an exclusive licensing agreement. The agreement is for a license of compounds identified from collaborative …
Share

21 April
H3 Biomedicine Extends Collaboration with Foundation Medicine to Develop Precision Therapies for Cancer

CAMBRIDGE, Mass.–(BUSINESS WIRE)–H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai’s global Oncology Business Group, today announced that is has extended its multi-year collaboration with Foundation Medicine, Inc. for the discovery and development of precision …
Share

25 January
Eisai’s Lenvatinib Meets Primary Endpoint in Late-Stage Hepatocellular Carcinoma Study

WOODCLIFF LAKE, N.J., Jan. 25, 2017 /PRNewswire/ — Eisai Inc. today announced positive topline results from the randomized, multicenter Phase 3 trial (Study 304) evaluating the company’s multiple receptor tyrosine kinase inhibitor, lenvatinib (marketed as Lenvima®), for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). The trial achieved …
Share

12 December
Eisai and Merck Announce New Interim Data Investigating Keytruda in Combination with Halaven in TNBC

KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced new interim data investigating Merck’s anti-PD-1 therapy, KEYTRUDA®(pembrolizumab), in combination with Eisai’s microtubule dynamics inhibitor, HALAVEN® (eribulin), in patients with metastatic triple-negative breast cancer (TNBC). Findings presented during …
Share

28 October
Eisai Initiates Two Phase 3 Trials with Fycompa in Children with Epilepsy

WOODCLIFF LAKE, N.J., Oct. 28, 2016 /PRNewswire/ — Eisai Inc. announced today the initiation of two multi-center, global Phase 3 clinical trials assessing FYCOMPA® (perampanel) CIII in two different patient populations: patients age 2 years and above with inadequately controlled seizures associated with Lennox-Gastaut Syndrome (LGS) (Study 338), a rare …
Share

Page 2 of 3«123 »